Findings

What do systematic reviews say?

7 questions · 7 findings · 5 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 1 · 14.3%High 1 · 14.3%

PEG vs placebo

Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation

PEG showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 0 [0.02, 1.51]
2 studies · 101 participants
Low

PEG vs lactulose

Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation

PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 2 [0.37, 15.96]
2 studies · 145 participants
Low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

All other (non‐serious) adverse events · people with chronic hepatitis C

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 4981 participants
Very low

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Serious adverse events Number of events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.3]
4 studies · 3900 participants
Low

Certolizumab pegol vs placebo

Serious adverse events · Patients with active Crohn's disease

Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.35 [0.93, 1.97]
4 studies · 1485 participants
Moderate

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Serious adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
Peto OR 1.47 [1.13, 1.91]
9 studies · 3927 participants
High

Certolizumab pegol vs placebo

Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.84 [0.4, 1.78]
Studies not reported
Low